Abivax ADR

ABVXNASDAQ · USD
87.58USD0.00 (-2.91%)
225

Abivax ADR (ABVX) Covered Calls

Abivax ADR trades in the Biotechnology industry with an IV Rank of 5.16%, low versus the past year. ABVX's highest covered call setup is the $150.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 66.30% out of the money with 8 days to expiration, a 66.35% return until expiration, and a 3,027.34% theoretical annualized return. Across the setups shown, annualized returns run from 806.61% to 3,027.34% at strikes between $93.00 and $195.00, with 1 to 36 days to expiration, as of Nov 12, 2026.

Read more

Running ABVX covered calls helps you generate income from Abivax ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABVX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ABVX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABVX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABVX covered call is worth writing.

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.

2026-11-208150.0066.300.050.155985.0066.353027.34-0.06+0.024,2270.10
2026-11-208130.0044.120.050.153985.0044.182015.69-0.06+0.022,1160.10
2026-11-208120.0033.040.100.202990.0033.151512.40-0.11+0.031,5000.10
2026-11-13193.003.100.201.20300.003.331213.97-0.22+0.274981.00
2026-12-1836195.00116.190.050.1510485.00116.241178.56-0.06+0.011,0190.10
2026-12-1836180.0099.560.100.308990.0099.671010.52-0.11+0.021,0490.20
2026-12-1836175.0094.010.100.208490.0094.12954.31-0.11+0.021,1750.10
2026-11-2715125.0038.580.100.953490.0038.69941.50-0.11+0.073390.85
2026-12-1836170.0088.470.100.407990.0088.58898.11-0.11+0.038390.30
2026-11-2715120.0033.040.100.502990.0033.15806.61-0.11+0.05980.40

As of Nov 12, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank5.16% Low
  • Market cap (M$)7,668
  • 52 weeks high-41.15%
  • 52 weeks low25.45%
  • Analyst recommendationStrong Buy
    1.28
  • Target price$157.26
    79.56% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-21
  • P/E—
  • Future P/E—
  • EPS (ttm)-6.10
  • EPS growth next 5 years34.25%

As of Nov 13, 2026